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Background: Neoadjuvant radiochemotherapy (RCT) is now part of the armamentarium of cancer of the lower and
middle rectum. It is recommended in current clinical practice prior to surgical excision if the lesion is classified
T3/T4 or N+. Histological complete response, defined by the absence of persistent tumor cell invasion and lymph
node (ypT0N0) after pathological examination of surgical specimen has been shown to be an independent
prognostic factor of overall survival and disease-free survival. Surgical excision is usually performed between 6 and
8 weeks after completion of CRT and pathological complete response rate ranges around 12%. In retrospective
studies, a lengthening of the interval after RCT beyond 10 weeks was found as an independent factor increasing
the rate of pathological complete response (between 26% and 31%), with a longer disease-free survival and
without increasing the operative morbidity. The aim of the present study is to evaluate in 264 patients the rate of
pathological complete response rate of rectal cancer after RCT by lengthening the time between RCT and surgery.
Methods/design: The current study is a multicenter randomized trial in two parallel groups comparing 7 and
11 weeks of delay between the end of RCT and cancer surgery of rectal tumors.
At the end of the RCT, surgery is planified and randomization is performed after patient’s written consent for
participation. The histological complete response (ypT0N0) will be determined with analysis of the complete
residual tumor and double reading by two pathologists blinded of the group of inclusion. Patients will be followed
in clinics for 5 years after surgery. Participation in this trial does not change patient’s management in terms of
treatment, investigations or visits. Secondary endpoints will include overall and disease free survival, rate of
sphincter conservation and quality of mesorectal excision. The number of patients needed is 264.
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Rectal cancer represents 12 000 new cases each year in
France [1]. Its management is based on a multidisciplin-
ary management with radiotherapy, chemotherapy and
surgery.Surgery
Surgery consisting of total excision of the mesorectum
has improved over time. The studies of Heald [2,3] have
showed that local recurrence rate was directly related to
the preservation of the fascia recti during the dissection
of the rectum. In countries where this surgical procedure
was emphasized, the local recurrence rate and life ex-
pectancy after treatment of rectal cancer were improved
[4,5]. In Sweden, after learning of the mesorectal exci-
sion technique, 447 patients were compared to older co-
horts, the local recurrence rate at 5 years was increased
from 20.5% to 8.2% and 5-year survival of 65.8% to
77.3% (p < 0.001 for both comparisons).Radiotherapy
Before the widespread diffusion of the technique of
mesorectal excision, many studies, including 4 randomized
studies, had compared pre-operative radiotherapy (RT) ver-
sus surgery alone [6-9]. Results showed only a benefit in
terms of local control with a reduction of 10% to 5% of the
recurrence rate local for patients with optimal dissection of
the mesorectum, but no survival benefit. In 1997, a ran-
domized study in 1168 subjects showed an improved sur-
vival with neoadjuvant RT: survival at 9 years was 65% for
patients with no radiotherapy compared to 74% for patients
with neoadjuvant RT (p = 0.002) [9]. Local recurrence for
patients treated by surgery alone was also more frequent
(27% (150/557) compared to 11% (63/553), p < 0.001) [9].
This finding was explained by a suboptimal surgical resec-
tion without complete mesorectum excision. As a conse-
quence, an international randomized trial study comparing
RT + surgery versus surgery alone with quality control of
excision mesorectum [10] was conducted in 1805 patients.
The results confirmed a higher rate of local control at
2 years in patients with preoperative radiotherapy (2.4%
vs. 8.3%, p < 0.001), with no difference in terms of survival
(82% vs. 81.8%, p = 0.84). Early postoperative complica-
tions were higher in the RT + surgery group (48% vs. 41%,
p < 0.01) [11]. After a minimum of 5 years of follow-up,
long-term complications; were more frequent in the pre-
operative radiotherapy group with (62% and 56% versus
38% and 33% of episodes of incontinence and pad wearing
respectively; p < 0.001) [12]. As postoperative morbidity
and results functional obtained after preoperative RT were
very significantly altered, the authors recommended such
treatment only in patients at high risk of local recurrence.
These recommendations were proposed by the Frenchexperts for the treatment of rectal cancer and were ap-
proved by the Haute Autorité de Santé in 2007 [13].
Chemoradiotherapy
Other studies have evaluated the impact of adding chemo-
therapy to RT [14,15]. The randomized trial of Bosset
et al. included between 1993 and 2003, 1011 patients
with rectal cancer T3 or T4 and analysed the impact of
addition of chemotherapy based on 5-fluorouracil to RT
45Gy [14] compared with preoperative RT alone. The
complete response rate (pT0) on resected specimen was
5.3% in the RT alone group and 13.7% in the chemo-
radiotherapy (CRT) group (odds ratio = 2.84, 95%CI:
1.75 to 4.59, p < 0.0001) [15]. No benefit in overall sur-
vival or disease-free survival was observed in CRT group
despite a significant improvement rate of local recurrence
at 5 years (8.7% in the CRT compared to 17.1% after RT
alone vs., p = 0.002). However, the results cannot be gener-
alized because of the lack of uniform total mesorectal exci-
sion for all patients included in this study.
However, CRT has allowed the team of Pr. Habr-Gama
to obtain a complete clinical regression of tumor rectal in
26.8% of cases (71/265 patients) [16]. The protocol
consisted of 50 Gy radiation therapy combined with
chemotherapy based on 5-fluorouracil and leucovorin.
This group of patients had not been operated and simple
surveillance without resection was performed. After a
mean follow-up of 57 months, only 2 patients (2.8%) had
local recurrence and 3 had distant metastases. The 5-year
recurrence rate was 7%. The complete clinical response
was associated with better overall survival at 5 years: 100%
versus 88% (p = 0.01).
In a retrospective series of the Cleveland Clinic,
among 238 patients treated with neoadjuvant CRT, 58
(24.4%) had a ypT0N0 tumor on pathological exam.
Postoperative morbidity was similar in the neoadjuvant
CRT group and in the no-pCR group, but there was a
better local control (5 years local recurrence rate: 0% vs.
10.6%, p < 0.001) [17].
Complete response: the importance of the period
between the end of radiotherapy and surgery
The median complete response rate is about 12% [7-27%]
in the main series of rectal cancer treated with RT or RCT
[18-31]. A randomized study in 1999 had already found an
effect in tumor reduction after RT between two intervals
(2 weeks or 7 weeks) clinical response increased from
53.1% to 71.7% (p = 0.007) and pCR or near complete
(persistence of some tumor cells) increased from 10.3% to
26% (p = 0.0054) [21]. The results of this study cannot be
generalized, considering the use of a technique of meso-
rectal excision other than the widely distributed and ad-
ministered neoadjuvant therapy (RT alone of 40 Gy).
However the interest of extending the period after RT was
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rectal cancers treated with neo-adjuvant RCT (50 Gy +
5-fluorouracil), the rate of complete response increased
from 9% to 23% between patients operated on before
the 40th day (between 6th and 7th week) and those oper-
ated on after waiting more than 7 weeks (p = 0.09) [27].
Following the work of Prof. Habr-Gama, other au-
thors have attempted to identify factors associated with
a pCR after surgical resection. The first study published
by Tulchinsky et al. [29] in 2008 reported the retro-
spective findings on the time between preoperative CRT
(45–50 Gy + 5-fluorouracil) and surgery (less or more
than 7 weeks) in 132 patients operated on by anterior re-
section or abdomino-perineal resection between 2000 et
2006. The rate of pCR or near complete (persistence of
microscopic foci of adenocarcinoma in the rectal wall
without lymph node) was 28% in the resected specimen.
The single independent factor associated with a good re-
sponse was the period between the end of RT and surgery:
17% in the group operated <7 weeks against 35% in the
other group operated after 7 weeks (p = 0.03). There was
no association between the duration of interval before sur-
gery and postoperative morbidity (complications, transfu-
sion, duration of hospitalization). Kalady et al. studied
retrospectively (1997–2007) records of 306 patients oper-
ated for a rectal cancer after CRT (50 Gy and 5-
fluorouracil) [30]. The dose of radiation received in each
group was similar. The rate of pCR (ypT0N0) was 24% in
this study. Time between the end of RCT and surgery, with
a cut-off estimated at 8 weeks was the single prognostic
factor for pCR in uni- and multivariate analysis (OR =
2.63-95%CI [1.13 to 6.12], p = 0.02). A. The pathological
complete response rate increased from 16.3% (14/86) in
the group operated < 8 weeks against 30.8% (28/91) for
other (p = 0.03). The authors observed that the period be-
tween 8 and 10 weeks showed the greatest number of
complete responses and that there was no more gain over
14 weeks. This retrospective study did not give any explan-
ation on the reasons for variations in the time between the
end of radiotherapy and surgery [32]. The group of patients
with pCR had a better overall survival with a follow-up of
60 months (91% versus 80%, p = 0.046) and less local re-
currence at 5 years (0% versus 11%, p = 0.023). A Korean
study analyzed retrospectively the data from 12 centers of
306 patients with a tumor classified ypT0 following CRT.
This study confirmed the favourable impact of pCR after
neoadjuvant CRT on survival: the 5-year overall survival
of these patients having 93.4% of tumors initially classified
T3 or T4 was 92.8%. Disease-free survival at 5 years was
84.6%. Finally, Kalady et al. compared the outcomes in a
retrospective series of 177 patients operated for a rectal
cancer after neoadjuvant treatment between patients oper-
ated before 8 weeks or after 8 weeks following the end of
CRT between 1997 and 2007. Postoperative morbidity ormortality were similar between the two period group. The
rate of pCR was lower in the <8 weeks group compared
with the > 8 weeks group (16.2% vs. 31.1%, p = 0.027).
Moreover, the 3 years local recurrence rate was significant
lower in the >8 weeks (1.2% vs. 3.9%, p = 0.04) [33].
All these publications are retrospective and the real
impact of the delay between the end of CRT and surgery
is still a matter of debate [34].
Aims
The main objective of our study is to evaluate in a ran-
domized trial the impact of a longer interval between the
end of CRT and rectal cancer surgery (7 weeks versus
11 weeks) on the rate of pathological complete response.
Secondary outcomes include overall and disease free sur-
vival, quality of mesorectal excision, rate of sphincter
preservation.
Methods and design
This study is a multicenter randomized open-label con-
trolled trial in parallel groups, comparing two periods be-
tween the end of CRT and cancer surgery of rectal
tumors: 7 weeks versus 11 weeks. This study has been ap-
proved by a national Institutional Review Board: the Re-
gional Comity of Patients Protection of South-West I,
N°1-12-19:30/08/12 and by the National Agency of Medi-
cine and Medical Products (ANSM: B111580-10). This
study is supported by a grant from the French Ministry of
Health (PHRCN 2011, AOM 11314). The research carried
out will be on accordance with Helsinki declaration.
Participants
The institutional promoter is the AP-HP (Assistance
Publique-Hôpitaux de Paris – DRCD: Département de la
Recherche Clinique). Patients are included from several
departments of surgery or oncology (n=26) in France
(see list of participating centers in the Acknowledgments
section). All participating sites signed a convention with
the DRCD for ethical approval before beginning of inclu-
sion. All patients must fulfil the following criteria: T3/T4
and/or TxN+mid or low third rectal cancer and com-
pleted RCT. The complete inclusion and exclusion criteria
are given in Table 1. After oral and written explanation
about the purpose of this study, the patient gives his
written consent agreeing to participate to the protocol
(Figure 1).
Randomization
After completion of the pre-intervention assessments,
the patients are randomly assigned to the period group
(ratio 1:1) by Internet. Blocked centralized randomisa-
tion with stratification by centre will be prepared by
URC-Est.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• age over 18 years, no age limit higher • Patient with metastasis,
• Performance status evaluated by the Eastern Cooperative Oncology
Group (ECOG) score: 0-1
• T1 or T2N0 tumor classified by echo -endoscopy and MRI,
• rectal tumor with lower pole is more than 12 cm from the anal margin
or 10 cm from the dentate line,
• Patients with cancer of the middle or lower rectum (lesion located
within 10 cm from the dentate line or 12 cm from the anal margin)
proved by pathology,
• Patient did not complete the full protocol of radiotherapy,
• History of tumors (other than basal cell carcinoma and / or carcinoma in
situ of the cervix)
• T3-T4N0, TxN+ on ultrasound-endoscopy and MRI, without secondary
localization (M0) on the thoraco-abdominal (or chest radiography and
abdominal ultrasound)
• A patient with impaired or incompetent
• investigator by not allowing him a good understanding of the
requirements of the study, person under guardianship, persons under
guardianship, persons deprived of their liberty by judicial or
administrative body, adult subject to legal protection or unable to
consent.
• Patient who received a protocol between 45–50 Gy of radiotherapy and
chemotherapy based on 5-fluorouracil for an average duration of 5 weeks
for the management of rectal cancer,
• Curative surgical treatment planned following radiochemotherapy with
total mesorectal excision,
• Free and informed consent signed by the patient,
• Patient affiliated to a social security scheme or beneficiary of such plan
(except AME)
• Patient able, according to the investigator, to comply with the
requirements of the study.
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Surgical resection with total mesorectal excision (TME)
The anaesthesia consultation is planned before the sur-
gery according to the habits of each department. Partici-
pation in the study does not alter the anaesthetic
procedures. The patient is admitted the day before sur-
gery in the surgical ward.
The type of resection (coloanal anastomosis, abdomino-
perineal resection, delayed anastomosis, drainage, laparo-
scopic approach…) is not influenced by the participation
to this protocol. As the rectal tumor is located in the mid-
or low rectum a TME is required.
Pathological exam
The pathological exam required has been already pub-
lished in the National French Guidelines [35]. A stan-
dardized routine pathology examination was performed
using the protocol of Quirke et al. [36]. After fixation in
10% formalin and inking to assess the circumferential
margin, the whole tumor was cut transversely. Accor-
ding to the macroscopical features, different techniques
for sampling of tumor tissues were applied in order to
avoid any under staging of the specimen:
– If there was only ulceration and fibrotic changes
without any visible tumoral lesion or if the tumor
residual measured less than 3 cm in diameter, the
lesion was examined entirely;
– If the residual tumor measured more than 3 cm in
diameter, one selected block per cm of tumor wasprocessed. If the first selected blocks were free of
tumor, complementary blocks were taken and the
macroscopically residual lesion was examined in
toto. A diagnosis of pCR will only be made after
examination of the whole macroscopically residual
lesion [37]. The tumor response is evaluated by
inclusion of all residual tumor and the response to
CRT is graded with the scales of Rodel and Dvorak
[22,38]. A double reading of slides will be made for
each patient by two independent pathologists
blinded to the randomization group of the patient to
confirm the ypT stade as the two regression scores.
In case of disagreement between the two
pathologists, they should jointly give a mutual result.
Outcomes and assessments
Primary outcome
Rate of histological complete response after double read-
ing by two different pathologist.
Secondary outcomes
Mobidity, sphincter preservation rate, overall and disease-
free survival.
Surgical data
During surgery, the operating data are provided on the e-
CRF (digital rectal examination under general anaesthesia,
type of surgery (anterior resection or abdomino-perineal re-
section), operative time, intraoperative bleeding, macroscopic
Figure 1 Flow chart.
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limit of resection.
Morbidity and mortality
The postoperative complications are noted by the sur-
geon in the e-CRF during hospitalization (about 10–
15 days) and during the first 3 months. Postoperative
death is defined as death occurring within 30 postopera-
tive days or during the first hospitalization. Postoperative
complications are defined by the occurrence of medical
or surgical complications within 90 postoperative daysor during the first hospitalization. Morbidity will be eval-
uated with the new classification of surgical complica-
tions by Dindo et al. which includes 5 grades [39,40].Pathological exam
Usual data are recorded: distal and circumferiential mar-
gins, number of resected and invaded nodes, tumoral
differenciation, presence of vascular embols (veinous or
lymphatic, intra or extra-mural), perineural engainement,
quality of mesorectal excision. The resected specimen will
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Cancer (AJCC) criteria (7th version).
Rate of sphincter preservation
Comparison between the planned intervention at the
time of the randomisation and the resection performed
after peroperative digital exam will be performed.
Oncological follow-up
Patients will be followed in clinics for 5 years according to
the habits of each department. Usual follow-up is com-
posed of clinical exam, CEA analysis, CT-scan or Chest
Radiography with abdominal ultra-sound every 3–4 months
during the first three years and every 6 months for the last
two years.
Samples size and statistical considerations
With a sample of 264 patients, GRECCAR6 trial has
80% of power to detect at least a two fold increase in the
complete response rate in the 11 weeks group compared
to the 7 weeks group. This hypothesis assumes that the
complete response rate in the 7 weeks group is similar
to the usual rate of complete response after 6–8 weeks
(12% (Kalady et al. Bosset et al. Hiotis et al.)), with an
expected complete response rate in the 11 weeks group
of 26% and 10% of drop-outs, using a two-sided test at
the 0.05 significance level.
Intention to treat analysis of the primary endpoint will
be performed once all randomized patients have
6 months of follow-up. Analysis of survival will be
performed after at least 5 years of follow-up. A futility
analysis [41] is planned after randomization after 132 pa-
tients, using a Bayesian statistical interference, with no
impact on Type 1 error [42].
Discussion
While several retrospective studies has emphasised the
role of longer interval on efficiency of radiochemother-
apy on histological tumoral response, this multicentric
randomized trial is the first to evaluate this factor. The
major drawback of previous studies is that no explana-
tions are given on the reasons for variations in the time
between the end of radiotherapy and surgery [29,32,43].
Indeed, the time interval was decided by the surgeon or
maybe in case of favourable clinical response, mainly au-
thors advocate other factors such as patient morbidity or
logistical scheduling issues [33].
This trial could then identify a simple and cheap factor
influencing the rate of pCR. While is it still not obvious
that pCR is a good suggorate marker of the overall sur-
vival [44] based on previous randomized control trial on
CRT, it is probable that it could be a prognosis marker
of rectal conservation. One publication showed thatpatients operated after 8 weeks may have significantly
less local recurrences.
Indeed, if waiting 4 more weeks increase the rate of
pCR, more patients could avoid a morbid surgical pro-
cedure such as an abdomino-perineal resection. This
new management is still limited due to the actual diffi-
culties to identify patients with pCR before surgery.
Adavances in radiological imaging may facilitate this im-
portant point.
Finally, this long delay would allow the use of chemo-
therapy during this 3 months waiting period. This could
reduce the risk of synchronous metastasis that may
occur during the waiting period.Competing interests
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